(firstQuint)An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects.

 This is a single center, open label study on healthy volunteers.

 The study will consist of up to 2 parts; the decision to proceed to the optional second part will be made following review of Part 1 data.

 Part 1 and optional Part 2 have randomized, 2 period crossover designs.

 Subjects will randomized to 1 of 2 treatment sequences in order to receive 2 single doses of FDL169 on separate occasions, one as a sublingual administration and one as an oral administration.

 There will be a minimum washout period of 10 days between FDL169 administrations.

 The duration of each part is approximately 7 weeks from screening to follow up.

.

 An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects@highlight

Two parts, two periods, crossover study with part 2 is optional.

 In both parts, subjects will be randomized to sequentially receive both sublingual and oral formulations of FDL169.

